Abstract Aquaporin-1 (AQP1), a membrane water channel protein, is expressed exclusively in the choroid plexus epithelium in the central nervous system under physiological conditions. However, AQP1 expression is enhanced in reactive astrocytes, accumulating in brain lesions of Creutzfeldt-Jakob disease and multiple sclerosis, suggesting a role of AQP1-expressing astrocytes in brain water homeostasis under pathological conditions. To clarify a pathological implication of AQP1 in Alzheimer disease (AD), we investigated the possible relationship between amyloid-beta (A ) deposition and astrocytic AQP1 expression in the motor cortex and hippocampus of 11 AD patients and 16 age-matched other neurological disease cases. In all cases, AQP1 was expressed exclusively in a subpopulation of multipolar Wbrillary astrocytes. The great majority of AQP1-expressing astrocytes were located either on the top of or in close proximity to A plaques in AD brains but not in non-AD cases, whereas those independent of A deposition were found predominantly in non-AD brains. By Western blot, cultured human astrocytes constitutively expressed AQP1, and the levels of AQP1 protein expression were not aVected by exposure to A 1-42 peptide, but were elevated by hypertonic sodium chloride. By immunoprecipitation, the C-terminal fragment-beta (CTF ) of amyloid precursor protein interacted with the N-terminal half of AQP1 spanning the transmembrane helices H1, H2 and H3. These observations suggest the possible association of astrocytic AQP1 with A deposition in AD brains.
Introduction
The aquaporins (AQPs) constitute a family of integral channel proteins that facilitate the osmotically driven bidirectional water transport across the cell membrane [2, 54] . Previous studies identiWed at least 13 mammalian members, widely expressed in various Xuid-transporting epithelial and endothelial cells. AQP1, AQP2, AQP4, AQP5 and AQP8 are chieXy water selective, while AQP3, AQP7, AQP9 and AQP10 transport glycerol in addition to water. Among AQP family members, AQP1, AQP4 and AQP9 are expressed in the central nervous system (CNS) [2, 54] . AQP1, initially identiWed in red blood cells and renal proximal tubular epithelium, is expressed constitutively in the apical surface of choroid plexus epithelium in the CNS [8, 39] . The crystal structure of AQP1 water channel is composed of a dumbbell-shaped homotetramer of 28-kDa subunits, each of which contains six transmembrane domains and an extracellular epitope that deWnes the Colton blood group antigen on erythrocyte membranes [10] . Outside the brain, AQP1 is expressed in retinal amacrine cells [24] , Schwann cells [14] , dorsal root ganglia neurons [48] , lungs and hepatobiliary epithelium. AQP1-null individuals negative for the Colton antigen, having homozygous mutations in the AQP1 gene exhibit a defect in urinary concentration and reduced pulmonary vascular permeability after overloading Xuid [27, 28] . AQP1-null mice show a decrease in cerebrospinal Xuid (CSF) production, indicating a pivotal role of AQP1 in CSF secretion in the CNS [42] . Although AQP1 is expressed widely in vascular endothelial cells outside the CNS, the levels of AQP1 expression are very low in brain endothelial cells, and no expression is found in cultured rodent astrocytes [12] .
Earlier studies showed that high-grade astrocytoma cells intensely express both AQP1 and AQP4, suggesting the involvement of water channel upregulation in development of tumor-associated brain edema [41, 45] . AQP1-null mice show a reduction in tumor vascularity and migratory capacity [46] . In contrast, overexpression of AQP1 in Wbroblast in culture accelerates anchorage-independent cell growth characteristic of malignant transformation [19] . Mouse melanoma cells, overexpressing AQP1 show an increase in metastatic potential [21] . AQP1 plays a central role in macrophage and leukocyte recruitment during acute inXammation [40] . Based on these observations, it is proposed that AQP1 regulates cell growth and migration by a mechanism that involves cytoskeletal reorganization, triggered by water transport at the leading edge of proliferating and migrating cells [54] . Furthermore, AQP1 plays a role in apoptotic cell shrinkage by regulating the cell volume [22] .
Increasing evidence indicates that astrocytes express AQP1 in CNS under pathological conditions. The expression of both AQP1 and AQP4 is enhanced markedly in reactive astrocytes accumulating in the lesions of subarachnoid hemorrhage [4] , contusion [51] , Creutzfeldt-Jakob disease (CJD) [44] , cerebral infarction [47] , and multiple sclerosis (MS) [47] . However, the precise mechanism accounting for upregulation of AQP1 in reactive astrocytes remains unknown. A recent study showed that the expression of AQP1 but not that of AQP4 is augmented in cortical astrocytes at the early stage of Alzheimer disease (AD), suggesting a pathological role of abnormal regulation of water transport in AD [43] . Because intracerebral accumulation of amyloid-(A ) plays a central role in the pathogenesis of AD [16] , and activated astrocytes are often associated with A plaques in AD brains [37, 55] , we investigated the possible relationship between A deposition and AQP1 expression in astrocytes in the cerebral cortex of AD.
Materials and methods

Human brain tissues
Ten micron-thick serial sections were prepared from autopsied brains of 11 AD patients composed of Wve men and six women with the mean age of 71 § 9 years and 16 other neurological disease (non-AD) patients composed of nine men and seven women with the mean age of 67 § 12 years. The non-AD cases include three patients with Parkinson disease (PD), three with multiple system atrophy (MSA), four with amyotrophic lateral sclerosis (ALS), three with myotonic dystrophy, one with spinal and bulbar muscular atrophy (SBMA), one with schizophrenia, and one with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). The average of brain weight was 1,038 § 163 g in AD cases and 1,220 § 173 g in non-AD cases. Brain tissues of the motor cortex and hippocampus were Wxed with 4% paraformaldehyde (PFA) and embedded in paraYn. In the present study, we tentatively deWned the hippocampus and parahippocampal cortex as the hippocampus. All AD cases were satisWed with the Consortium to Establish a Registry for Alzheimer's disease (CERAD) criteria for diagnosis of deWnite AD [34] . They were categorized into stage C of amyloid deposition and stage VI of neuroWbrillary degeneration, following the Braak's staging [9] . The autopsied brain samples were obtained from Research Resource Network (RRN), Japan. Written informed consent was obtained from all the cases examined. The Ethics Committee of National Center of Neurology and Psychiatry approved the present study.
Human astrocytes in culture
Human astrocytes were established from neuronal progenitor (NP) cells isolated from a human fetal brain (BioWhittaker-Cambrex, Walkersville, MD, USA). NP cells plated on a polyethyleneimine-coated surface were incubated in DMEM/F-12 medium (Invitrogen, Carlsbad, CA, USA) containing an insulin-transferrin-selenium (ITS) supplement (Invitrogen), 20 ng/ml recombinant human EGF (Higeta, Tokyo, Japan), 20 ng/ml recombinant human bFGF (PeproTech EC, London, UK), and 10 ng/ml recombinant human LIF (Chemicon, Temecula, CA, USA). For the induction of astrocyte diVerentiation, NP cells were incubated for several weeks in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 g/ml streptomycin (feeding medium). The inclusion of FBS in the culture medium induced vigorous proliferation and diVerentiation of astrocytes accompanied by a rapid reduction in non-astroglial cells. The purity of astrocytes exceeded 98% by GFAP immunolabeling, as described previously [47] .
To determine the eVects of stress-inducing stimuli on AQP1 expression, human astrocytes were incubated for 48 h in the feeding medium with inclusion of 10 M human A 1-40 peptide (Peptide Institute, Osaka, Japan), 10 M human A 1-42 peptide (Peptide Institute), 100 mM NaCl, 100 M sodium nitroprusside, a NO donor (SNP; MerckCalbiochem, Tokyo, Japan), 10 M all trans retinoic acid (RA; Sigma, St Louis, MO, USA), 100 nM phorbol 12-myristate 13-acetate (PMA; Sigma), 1 mM dibutyryl cyclic AMP (dbcAMP; Sigma), 10 M MG-132, a proteasome inhibitor (Merck-Calbiochem), or 1 M thapsigargin, an endoplasmic reticulum (ER) stress inducer (TG; Sigma), or incubated in the serum-free DMEM/F-12 medium containing 100 M hydrogen peroxide.
Double-labeling immunohistochemistry
After deparaYnation, tissue sections were heated in 10 mM citrate sodium buVer, pH 6.0 by autoclave at 125°C for 30 s in a temperature-controlled pressure chamber (Dako, Tokyo, Japan). For A immunolabeling, tissue sections were pretreated with formic acid for 5 min at room temperature (RT). All tissue sections were incubated with phosphate-buVered saline (PBS) containing 10% normal goat serum (NGS) at RT for 15 min to block non-speciWc staining. Then, tissue sections were initially stained at 4°C overnight with primary antibodies listed in Table 1 , followed by incubation with alkaline phosphatase (AP)-conjugated secondary antibody (Nichirei), and colorized with New Fuchsin substrate. The speciWcity of anti-AQP1 antibody (H-55, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-AQP4 antibody (H-80, Santa Cruz Biotechnology) was veriWed by Western blot analysis of HEK293 cells that express the transgene of human AQP1 or AQP4 as described previously [47] . In addition, we found that choroid plexus epithelial cells, representing a positive control cell type, were stained intensely by H-55 ( Supplementary  Fig. 1 ). After inactivation of the antibody by autoclaving the sections at 125°C for 30 s in 10 mM citrate sodium buVer, pH 6.0 following the manufacturer's instruction (Nichirei), they were treated for 15 min with 3% hydrogen peroxide-containing distilled water to block the endogenous peroxidase activity. Then, they were relabeled with diVerent primary antibodies listed in Table 1 , followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (Nichirei), and colorized with DAB substrate and counterstained with hematoxylin. For negative controls, the step of incubation with primary antibodies was omitted.
In 
Immunocytochemistry
For immunocytochemistry, the cells on cover glasses were Wxed with 4% PFA in 0.1 M phosphate buVer, pH 7.4 at RT for 5 min, followed by incubation with PBS containing 0.5% Triton X-100 at RT for 3 min. After blocking non-speciWc staining by PBS containing 10% NGS, the cells were incubated at RT for 30 min with a mixture of anti-GFAP antibody GA5 and anti-AQP1 antibody H-55. Then, they were incubated at RT for 30 min with a mixture of Alexa Fluor 568-conjugated anti-mouse IgG (Invitrogen) and Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen). After several washes, they were mounted with an anti-fade reagent containing 4Ј, 6Ј-diamidino-2-phenylindole (DAPI) (Invitrogen), and examined on the Olympus BX51 universal microscope. Negative controls were processed following all the steps, except for exposure to anti-AQP1 antibody.
Western blot analysis
To prepare total protein extract, the cells were homogenized in RIPA lysis buVer, composed of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, and a cocktail of protease inhibitors (Sigma), followed by centrifugation at 12,000 rpm for 10 min at RT. The supernatant was collected, solved in the lysis buVer containing 2.5 M urea, and separated on a 12% SDS-PAGE gel [47] . The protein concentration was determined by a Bradford assay kit (BioRad, Hercules, CA, USA). After gel electrophoresis, the protein was transferred onto nitrocellulose membranes, and immunolabeled at RT overnight with anti-AQP1 antibody H-55. Then, the membranes were incubated at RT for 30 min with HRPconjugated anti-rabbit IgG (Santa Cruz Biotechnology). The speciWc reaction was visualized by exposing to a chemiluminescent substrate (Pierce, Rockford, IL, USA). After the antibodies were stripped by incubating the membranes at 50°C for 30 min in stripping buVer, composed of 62.5 mM Tris-HCl, pH 6.7, 2% SDS and 100 mM 2-mercaptoethanol, the membranes were processed for relabeling with mouse monoclonal anti--actin antibody AC-15 (Sigma).
Immunoprecipitation analysis
To determine the molecular interaction between A and AQP1, the N-terminal half of AQP1, including the transmem- brane helices H1, H2 and H3 (amino acid residues 2-132; NTF), the C-terminal half of AQP1, including the transmembrane helices H4, H5 and H6 (amino acid residues 133-269; CTF) [10, 32] (GenBank accession No. NM_198098), and the C-terminal fragment (amino acid residues 597-695; CTF ) of amyloid precursor protein (APP) (NM_201414) were ampliWed by PCR using PfuTurbo DNA polymerase (Stratagene, La Jolla, CA, USA) and the sense and antisense primer sets following: 5Јccgaattccggccagcgagttcaagaagaag3Ј and 5Јfor the NTF of AQP1, 5'cggaattccggtgaactcgggccagggcct3Ј and 5Јcggggtaccccgctatttgggcttcatctccac3Ј for the CTF of AQP1, and 5Јand 5'cgggatcccgctagttctgcatctgctcaaagaa3Ј for the CTF of APP. After digestion with EcoRI, KpnI, XbaI or BamHI (New England BioLabs, Beverly, MA, USA), the PCR products were cloned in the expression vectors pCMV-Myc (Clontech, Mountain View, CA, USA) or p3XFLAG-CMV7.1 (Sigma) to express a fusion protein with an N-terminal Flag or Myc tag. At 48 h after co-transfection of the vectors, HEK293 cells were homogenized in M-PER lysis buVer (Pierce) supplemented with a cocktail of protease inhibitors. After preclearance, the supernatant was incubated at 4°C overnight with mouse monoclonal anti-Flag M2 aYnity gel (Sigma), rabbit polyclonal anti-Myc antibody-conjugated agarose (Sigma), or the same amount of normal mouse or rabbit IgG-conjugated agarose (Santa Cruz Biotechnology). After several washes, the immunoprecipitates were processed for Western blot with rabbit polyclonal anti-Myc antibody (Sigma) and mouse monoclonal anti-FLAG M2 antibody (Sigma).
Cell imaging analysis
The open reading frame (ORF) of the genes encoding AQP1 (amino acid residues 2-269) and the CTF or A 1-42 of APP were ampliWed by PCR using PfuTurbo DNA polymerase and the sense and antisense primer sets following: 5Јgcc agcgagttcaagaagaagctc3Ј and 5Јctatttgggcttcatctccaccct3Јfor AQP1, 5Јand 5'cgggatcccgctagttctgcatctgctcaaagaa3Ј for the CTF of APP, and 5Ј cgggatcccgctacgctatgacaacaccgcccac3Ј for A . After digestion with EcoRI, KpnI, XhoI or BamHI, the PCR products were cloned in the expression vectors pDsRed-Express-C1 (Clontech) or pcDNA3.1/NT/GFP-TOPO (Invitrogen) to express a fusion protein with an N-terminal DsRed or GFP tag. At 24-48 h after co-transfection of the vectors, HEK293 cells were Wxed brieXy in 4% PFA and mounted with the anti-fade reagent containing DAPI.
Tissue protein overlay analysis
To identify AQP1-binding targets in brain tissues in situ, we prepared recombinant human AQP1 protein tagged with Xpress (AQP1-Xpress), serving as a probe for tissue protein overlay. The ORF of AQP1 gene ampliWed by PCR described above was cloned into a prokaryotic expression vector pTrcHis-TOPO (Invitrogen), expressed in E. coli, and puriWed to obtain a fusion protein having an N-terminal Xpress tag. After deparaYnation, tissue sections were heated in 10 mM citrate sodium buVer, pH 6.0 by autoclave at 125°C for 30 s. They were treated with formic acid and 3% hydrogen peroxide, and then incubated at 4°C overnight with AQP1-Xpress at the concentration of 167 g/ml or with the same amount of recombinant -galactosidase fragment tagged with Xpress (LacZ-Xpress), serving as a negative control. After washing with PBS, the tissue sections were incubated at RT for 45 min with anti-Xpress antibody, followed by incubation with HRP-conjugated secondary antibody, and colorized with DAB substrate. After inactivation of the antibodies by autoclaving, the tissue sections were processed for immunolabeling with anti-A antibody, followed by incubation with AP-conjugated secondary antibody, and colorized with New Fuchsin substrate.
Results
The close association of AQP1-expressing astrocytes with A deposition in the cerebral cortex of AD First, we studied AQP1 and AQP4 expression in the motor cortex and hippocampus of 11 AD cases and 16 agematched other neurological disease (non-AD) cases by double-labeling immunohistochemistry with a combination of anti-AQP1 antibody, anti-AQP4 antibody, anti-A antibody, and antibodies against cell type-speciWc markers. In all cases, examined, AQP1 was expressed exclusively in multipolar Wbrillary astrocytes with highly-branched processes that often surround blood vessels and neurons (Figs. 1a, b, d-f, 2a, c-e). Neither NSE + neurons nor CD68 + microglia nor factor VIII-related antigen-positive vascular endothelial cells were immunolabeled with AQP1 antibody (Figs. 1e, f, 2a) . Approximately 70% of AQP1 + multipolar Wbrillary cells coexpressed an intense GFAP immunoreactivity, verifying that they represent a subpopulation of astrocytes with a unique morphology (Fig. 1d) . Importantly, AQP1-expressing astrocytes were either often located on the top of or in close proximity to A plaques in the motor cortex and hippocampus of AD, but rarely in non-AD cases (Fig. 1a) .
In contrast, AQP4 immunoreactivity was distributed more diVusely in the whole neuropil, gliotic and perivascular lesions, and the pia matter in the cerebral cortex of both AD and non-AD cases, although the staining was more intense in AD brains ( Fig. 2b; Supplementary Fig. 2) . In all the cases, multipolar Wbrillary astrocytes expressing an intense immunoreactivity for AQP4 were less prominently found,when compared with AQP1-expressing astrocytes. suggesting that AQP1 and AQP4 might play an overlapping but non-redundant role in astrocytic water channel function (Fig. 2c) . AQP1 + AQP4 + cells consisted of approximately 15% of all AQP-immunoreactive cells. Owing to the diVuse distribution of intense neuropil staining of AQP4, we could not clearly discriminate AQP4-immunoreactive astrocytes with or without a contact with A , making it highly diYcult to count exactly the number of AQP4-expressing astrocytes located in the proximity to A plaques.
Next, tissue sections of the motor cortex and hippocampus of AD and non-AD patients were processed for double-labeling immunohistochemistry with a combination of anti-AQP1 antibody and anti-A antibody. Then, we counted the number of A + AQP1
+ plaques (Figs. 1a, 2d ), A ¡ AQP1 + spots (Figs. 1b, 2e) , and A + AQP1
¡ plaques (Figs. 1c, 2f ) with the size exceeding the diameter of 50 m, by random scanning of the cerebral cortex at a 400£ magniWcation under microscope (Fig. 3a, b) . The average of percentages of A + AQP1
+ plaques was signiWcantly greater in both the motor cortex and hippocampus of AD than that of non-AD (P = 1.092E-05 in the motor cortex; P = 1.410E-05 in the hippocampus). In contrast, the average of percentages of A ¡ AQP1 + spots was signiWcantly greater in both the motor cortex and hippocampus of non-AD than that of AD (P = 1.865E-05 in the motor cortex; P = 5.035E-04 in the hippocampus). By counting of ten random high magniWcation Welds, the average of total Table 1 . a-c AQP1 (brown) and A (red), d AQP1 (red) and GFAP (brown), e AQP1 (brown) and CD68 (red), and f AQP1 (brown) and factor VIII-related antigen (red). Multipolar Wbrillary astrocytes expressing an intense AQP1 immunoreactivity are often located on the top of A deposition (a) In contrast, it was 0.6 § 1.9 for A and 2.7 § 1.8 for AQP1 in the motor cortex of non-AD, and 2.6 § 4.5 for A and 8.6 § 6.1 for AQP1 in the hippocampus of non-AD. Thus, the average number of A -immunoreactive plaques and AQP1-immunoreactive plaques/ spots, was elevated signiWcantly in the cerebral cortex of AD compared with non-AD (P = 1.217E-05 for A in the motor cortex; P = 6.416E-05 for A in the hippocampus; P = 1.092E-05 for AQP1 in the motor cortex; and P = 0.003 for AQP1 in the hippocampus). All of these observations suggest a close association of AQP1 with A deposition in the cerebral cortex of AD. Alternatively, the possibility should be considered that the population of A + AQP1 + plaques is much smaller in non-AD brains, because there existed less amounts of A deposition and smaller numbers of AQP1-immunoreactive astrocytes in the brains of non-AD cases. In this setting, A deposition might not be obligatory for induction of the astrocytic expression of AQP1.
The expression and induction of AQP1 in cultured human astrocytes
Since a subset of astrocytes intensely expressed AQP1 in AD and non-AD brains, in the next step, we investigated AQP1 expression in cultured human astrocytes. Consistent with high levels of AQP1 mRNA expression in cultured human astrocytes, as we reported previously [47] , virtually all of them expressed constitutively a discernible immunoreactivity for AQP1, located mostly on the plasma membrane and less abundantly in the cytoplasm (Fig. 4a-d) . The expression of AQP1 in astrocytes was further validated by Western blot. Cultured human astrocytes expressed constitutively a substantial amount of AQP1 protein with a molecular weight of 28-kDa, which represents the nonglycosylated form (Fig. 5a, lanes 1, 4, 6 ). They did not consistently express the glycosylated form with a larger molecular weight (data not shown). Then, cultured human astrocytes were exposed for 48 h to various stimuli that potentially aVect the levels of AQP1 expression. The levels of AQP1 protein expression were not aVected by treatment with either A 1-42 or A 1-40 peptide, but elevated markedly by exposure to 100 mM NaCl, modestly by 10 M MG-132, and reduced substantially by treatment with 100 nM phorbol 12-myristate 13-acetate (PMA) (Fig. 5 , panel a, lanes 2, 3, 5, 10, 12). Upregulation by NaCl and downregulation by PMA were veriWed by real-time RT-PCR analysis ( Supplementary Fig. 3 ). In contrast, the treatment with either sodium nitroprusside (SNP), hydrogen peroxide, retinoic acid (RA), dibutyryl cyclic AMP (dbcAMP), or thapsigargin (TG) did not aVect the levels of AQP1 protein expression ( Fig. 5 lanes 7, 8, 9 , 11, 13). These results suggest that human astrocytes that express substantial amounts of AQP1 protein under the baseline culture condition are fairly resistant to induction of AQP1 by non-osmotic stimuli.
Molecular interaction of AQP1 and CTF of APP
Finally, the molecular interaction between AQP1 and A was investigated by immunprecipitation of recombinant fusion proteins with distinct epitope tags coexpressed in HEK293 cells, followed by pull down with tag-speciWc antibodies. Since preliminary experiments suggested that the segment spanning A 1-42 alone is not enough to identify ¡ or A ¡ AQP1 + , per the total was calculated, and the average is shown as the bar with standard deviation. a Motor cortex. b Hippocampus. *P = 1.092E-05, **P = 1.865E-05, *** P = 1.410E-05, and ****P = 5.035E-04 the protein-protein interaction owing to its small size (4 kDa) on a conventional Tris-glycine SDS-PAGE gel, we have chosen the CTF of APP, spanning both A and the APP intracellular domain (AICD), expressed as a Flagtagged fusion protein. Alternatively, either the NTF or the CTF of AQP1 was expressed as a Myc-tagged fusion protein. Pull-down assay showed that the CTF of APP interacts with the NTF of AQP1, but not with the CTF of AQP1, indicating that the molecular interaction is not attributable to an artifact caused by overexpression in HEK293 cells (Fig. 6a, b , upper and lower panels; lane 2).
To obtain additional evidence to support the results of immunoprecipitation analysis, we conducted cell imaging analysis. Either the CTF or A 1-42 was expressed as a DsRedtagged fusion protein, while the full-length AQP1 was expressed as a GFP-tagged fusion protein. The CTF of APP, as well as A , was located chieXy in the cytoplasm, while AQP1 was expressed mainly on the plasma membrane, and AQP1 protein levels in cultured human astrocytes exposed to various stimuli. Cultured human astrocytes were exposed for 48 h to the stimuli, and then processed for Western blot analysis with anti-AQP1 antibody H-55. The identical blot was relabeled with anti--actin antibody AC-15. The panels consist of three distinct sets of experiments, composed of the set #1 (lanes 1-3) , the set #2 (lanes 4 and 5), and the set #3 (lanes 6-13) . The lanes (1-13) represent (1, 4, 6 ) untreated or vehicle-treated cells, (2) 
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none of them were expressed in the nucleus, when overexpressed in HEK 293 cells. A discernible GFP Xuorescence was also detected in the cytoplasm, where AQP1 was found to be colocalized with CTF of APP and A (Fig. 6c, panels a-f) .
To determine the in vivo molecular interaction between AQP1 and A , we performed tissue protein overlay analysis using recombinant human AQP1 protein spanning the entire ORF tagged with Xpress (AQP1-Xpress) that enables us to identify the expression of AQP1-binding proteins in situ. This probe was recognized by both anti-AQP1 antibody and anti-Xpress antibody (Fig. 7a, panels a and b ; lane 2). By tissue protein overlay, the AQP1-Xpress probe did not decorate the entire surface of A -immunoreactive plaques, but the core of the plaques often expressed a nodular or irregular-shaped AQP1-Xpress-immunoreactivity (Fig. 7b, panel a) . The AQP1-Xpress probe also reacted intensely with many neurons, neuropil, and microglia in AD brains, suggesting that these cells and constituents might express the molecules with AQP1-binding epitopes (Fig. 7b, panel a) . The AQP1-Xpress probe did not label multipolar Wbrillary astrocytes. In contrast, the LacZXpress probe did not react with neurons, microglia, astrocytes, or A plaques, excluding non-speciWc interaction via the Xpress epitope of recombinant proteins (Fig. 7b, panel b) .
Discussion
In the present study, we investigated the relationship between A deposition and astrocytic AQP1 expression in the motor cortex and hippocampus of 11 AD patients and 16 age-matched non-AD cases. We found that AQP1 was expressed exclusively in a subpopulation of multipolar Wbrillary astrocytes in all cases. The great majority of AQP1-expressing astrocytes were located either on the top of or in close proximity to A plaques in AD brains but not in non-AD cases, whereas AQP1-expressing astrocytes independent of A deposition were found predominantly in non-AD brains. By tissue protein overlay analysis, AQP1-Xpress-immunoreactivities, reXecting the existence of the molecules with AQP1-binding epitopes, were located in the core of A plaques in AD brains. A number of previous studies showed that astrocytes, keeping in touch with A plaques, are activated by A itself in AD brains [37, 55] . In line with the previous observations, we showed that AQP1-expressing multipolar Wbrillary astrocytes are closely associated with A deposition in AD brains. These observations suggest the hypothesis that A deposition might cause abnormal brain water homeostasis by interfering with astrocytic water channel function. The present study included solely AD brains classiWed into the most advanced stage of the disease. To evaluate the hypothesis described above, it is important to investigate AQP1 expression in AD brains at early stages with minimal deposition or diVuse plaques of A . Importantly, a recent study using Western blot and immunohistochemistry showed that the levels of AQP1 protein expression are signiWcantly elevated in the frontal cerebral cortex of AD at the Braak's stage II, where reactive astrocytes similar to multipolar Wbrillary astrocytes observed in the present study express a cell-surface punctuate AQP1 immunoreactivity [43] . In contrast, no diVerences are found in AQP1 protein levels between the stages V-VI of AD and the age-matched control cases, suggesting the possibility that upregulated expression of AQP1 on astrocytes in AD brains is a disease stage-dependent event [43] .
To obtain a deeper insight into our in vivo observations of close association of AQP1-expressiong astrocytes with A , we studied the molecular interaction between AQP1 and A in a transient expression system of HEK293 cells in vitro. By the pull-down assay, the CTF of APP interacts with the N-terminal half (amino acid residues 2-132; NTF) of AQP1 spanning the transmembrane helices H1, H2, and H3, which contains one of two NPA motifs pivotal for water transport function [2, 32] . A recent study indicated that the amino acid residues composed of Phe 58, His 182, Cys 191, and Arg 197 are involved in constituting the constriction region of water channel, while both His 76 and Val 155 act as a valve by dynamically blocking water permeation [49] . AQP1, along with the CTF and A , were colocalized on the cell-surface membrane and in the cytoplasm, when they were coexpressed in cultured cells. Although the primary site of AQP1 expression is the cellsurface membrane, the intracellular location of AQP1 has been reported previously. AQP1 integrates into the ER membrane, when overexpressed in HEK293 cells [11] . Secretin induces a redistribution of AQP1 protein from intracellular vesicles to the plasma membrane in cholangiocytes [33] . Importantly, both APP and AQP1 constitute transmembrane proteins, and A and AQP1 are enriched in lipid rafts of the plasma membrane [7, 52] , raising the possibility of a direct protein-protein interaction between A and AQP1 at cell-to-cell contact interfaces in situ.
However, it should be kept in mind that the binding of AQP1 to A in vitro does not always precisely reXect the in vivo situation of the interaction between AQP1-expressing astrocytes and A . Importantly, both reactive astrocytes and activated microglia express scavenger receptors that mediate the clearance of extracellularly-deposited Wbrillar A [1] . Therefore, it is meaningful to study in the next step the molecular interaction of AQP1 and Wbrillar A , and its physiological interference with water transport in an astrocyte culture model in vitro. Although the present study, in the absence of high-resolution immunoelectron microscopic analysis dose not provide deWnitive evidence to show the direct interaction between A and AQP1 in vivo, we could currently propose two diVerent working models of the molecular interaction of AQP1 and A ; (1) astrocytic AQP1 could interact with extracellular deposition of Wbrillary A (Fig. 8a) and (2) astrocytic AQP1 could interact with the A and/or AICD transmembrane/intracellular segment of endogenous APP (Fig. 8b) .
Regulatory mechanisms underlying AQP1 expression are highly complex. Systemic hyponatremia elevates the levels of expression of AQP1 on choroid plexus epithelial cells [35] . Thyroid transcription factor-1 (TTF1), expressed in choroids plexus epithelium, facilitates CSF production by enhancing AQP1 gene expression [25] . Hypertonic stress induces the expression of AQP1 in rodent renal medullary cells by activating extracellular signal-regulated kinase (ERK), p38 MAP kinase, and c-Jun N-terminal kinase (JNK), all of which regulate a hypertonicity-responsive element (HRE) located in the AQP1 promoter [53] . Acetazolamide inhibits the osmotic water permeability by reducing AQP1 protein expression [56] . Treatment with corticosteroids increases the levels of AQP1 protein expression in the capillary endothelium of the peritoneal membrane and the lung [26, 50] . AQP1 expression is induced in rat gliosarcoma cells by exposure to hypoxia, dexamethasone, and PDGF, and by incubating the cells in hypertonic culture media containing NaCl, D-glucose or fructose [17] .
Treatment with proteasome inhibitors elevates the levels of AQP1 protein expression in mouse Wbroblasts [29] . All of these observations suggest that distinct promoter elements are activated in response to osmotic and non-osmotic stimuli in diVerent cell types. We found that AQP1 expression in cultured human astrocytes is upregulated markedly by hypertonic sodium chloride, modestly by MG-132, and downregulated by PMA, an activator of protein kinase C (PKC). It is worthy to note that tetradecanoylphorbol 13-acetate (TPA), another activator of PKC, induces a rapid decrease in AQP4 mRNA in rat astrocytes in culture [38] .
The pathophysiological role of AQP1-expressing multipolar Wbrillary astrocytes in AD brains remains unknown. Increasing evidence indicate that AQP1 acts as a gas transporter, such as O 2 , CO 2 , and NO [6, 13, 18] . AQP1, by transporting NO out of endothelial cells and into vascular smooth muscle cells, plays a pivotal role in endotheliumdependent vasorelaxation [18] . AQP1 expression is markedly upregulated in rat lungs by hypoxia [13] . AQP1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells [23] . We showed previously that AQP1-expressing astrocytes accumulate in ischemic Fig. 8 Working models of the molecular interaction between AQP1 and A . AQP1 is composed of a homotetramer of 28-kDa subunits. Each monomeric subunit contains six transmembrane helices (H1-H6) with two hemipores with an AsparagineProline-Alanine (NPA) motif, which fold to form a water channel (see the reference [32] ). Pulldown assay suggested that the CTF of APP, composed of A and AICD, interacts with the N-terminal half of AQP1 spanning H1, H2, and H3. Two diVerent working models could be proposed for the molecular interaction of AQP1 and A ; a astrocytic AQP1 could interact with extracellular deposition of Wbrillary A , and b astrocytic AQP1 could interact with the A and/or AICD transmembrane/ intracellular segment of endogenous APP lesions of cerebral infarction and active demyelinating lesions of MS [47] . Because the production of NO and reactive nitrogen species (RNS), as well as reactive oxygen species (ROS), is markedly enhanced in the brains of ischemia, MS and AD [3] , the possibility exists that AQP1-expressing astrocytes with a great migratory capacity [54] act as a scavenger of RNS and ROS by patrolling the cortex of AD. However, treatment with SNP and hydrogen peroxide did not aVect the levels of AQP1 protein expression in human astrocytes in culture, suggesting that these stimuli do not directly upregulate AQP1 expression in astrocytes.
We found that the levels of AQP1 protein expression on cultured human astrocytes were not aVected by exposure to A 1-42 peptide at least within a 48 h-observation period, although we observed a drastic change in morphology of astrocytes, exhibiting the morphology with ruZed cell-surface membranes ( Supplementary Fig. 4 ). The molecular basis for this change remains unknown. Even though A desposition does not act as a potent inducer for AQP1 expression in cortical astrocytes in AD brains, the close association of AQP1 with A suggests that extensive A deposition could cause abnormal brain water homeostasis by interfering with astrocytic water channel function. Supporting this view, previous clinical studies showed that brain ion and water homeostasis is profoundly disturbed in AD [5, 20] . Recent studies have indicated that intracerebral accumulation of not only A oligomers but also that of the APP intracellular domain (AICD) aVects the gene expression involved in neuronal survival [36] . Human astrocytes produce A in response to TGF , suggesting that astrocytes might coexpress A , along with AQP1, when activated by cytokines in AD brains [30] . The great majority of APP holoprotein is located in intracellular membranous compartments in cultured astrocytes [15] . AQP1 is produced initially as a precursor protein with four transmembrane segment-spanning topology at the ER membrane, and following topological reorientation it is processed to form a mature protein with six transmembrane segment-spanning topology at the plasma mambrane [31] . After overexpression of the transgenes without signal peptide sequences in HEK 293 cells, the CTF of APP, as well as that of A 1-42 , was located chieXy in the cytoplasm, while AQP1 was expressed mainly on the plasma membrane and less abundantly in the cytoplasm. Although the overexpression experiments in HEK293 cells do not precisely reXect the physiological situation, a discernible colocalization was detected in the cytoplasm, not excluding the interaction in intracellular membranous compartments. The pull-down assay showed that the CTF , composed of both A and AICD, interacts directly with the NTF of AQP1, although these observations did not specify the AQP1-interacting domain of APP, either A or AICD, or both. Therefore, the possible scenario could be raised that astrocytic A and/or AICD segment of endogenous APP interacts with AQP1 either on the plasma membrane or at speciWc intracellular membrane compartments (Fig. 8b) . In addition, the hypothetical view could be proposed that A and AICD, by binding to AQP1, not only aVect water permeability, but also modulate signaling pathways in astrocytes essential for supporting neuronal survival in the brains of AD.
In conclusion, AQP1-expressing Wbrillary astrocytes, which represent a unique subset of astrocytes, might have a close association with A in the brains of advanced stages of AD, although there exists no deWnitive evidence to show the direct contact. However, these observations suggest the working hypothesis that A deposition could cause abnormal brain water homeostasis by interfering with astrocytic water channel function. Further studies, including the immunohistochemical analysis of various disease stages, high-resolution morphological analysis, and cell physiological analysis, are required to evaluate this hypothesis.
